Christian Hunter

[...] a high-growth industry!  The company is certainly worthy of a closer look...   Christian Hunter Austin, Texas [...]

[...] cesspool of bureaucratic dog barf. Way to go Washington!  Thanks so so much for the... Christian Hunter Austin, Texas [...]

[...] .  I also think, far more importantly, by using them they'll be safer. Enjoy,  Christian Hunter Austin, TX [...]

[...] youtube. Here's an excellent Wired article on the coming-together of Expert Labs. Enjoy, Christian Hunter Austin, Texas August, 6, 2012 [...]

[...] Ambien for its euphoric and sedative properties, that's why I was shocked to learn that in clinical trials, Belviq proved to be more abuse prone and addictive at high doses than Ambien!  And by [...]

[...] Ambien for its euphoric and sedative properties, that's why I was shocked to learn that in clinical trials, Belviq proved to be more abuse prone and addictive at high doses than Ambien!  And by [...]

[...] be evaluated and discontinuation of BELVIQ should be considered. 5.3 Cognitive Impairment In clinical trials of at least one year in duration, impairments in attention and memory were reported adverse [...]

[...] and FDA-approved patient labeling. Pregnancy (4) CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)- like Reactions: The safety of coadministration [...]

[...] and FDA-approved patient labeling. Pregnancy (4) CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)- like Reactions: The safety of coadministration [...]

[...] , dextromethorphan, St. John’s Wort): use with extreme caution due to the risk of serotonin syndrome. (7.1) USE IN SPECIFIC POPULATIONS • Nursing Mothers: Discontinue drug or nursing. (8. [...]

[...] be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight [...]

[...] be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight [...]

[...] be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight [...]

[...] mellitus). Table 2. Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients without Diabetes Mellitus BELVIQ 10 mg [...]

[...] mellitus). Table 2. Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients without Diabetes Mellitus BELVIQ 10 mg [...]

[...] mellitus). Table 2. Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients without Diabetes Mellitus BELVIQ 10 mg [...]

[...] fatties!  In fact it's probably a miracle we're not all dead by now...though this Belviq drug may just change all that. Just kidding.  It's not deadly... Anyhow, excited by the [...]

[...] a bunch of fatties!  In fact it's probably a miracle we're not all dead by now...though this Belviq drug may just change all that. Just kidding.  It's not deadly... Anyhow, excited by the news of a [...]

[...] fatties!  In fact it's probably a miracle we're not all dead by now...though this Belviq drug may just change all that. Just kidding.  It's not deadly... Anyhow, excited by the [...]

[...] operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ therapy does not affect them adversely [see Patient Counseling Information (17)]. Reference ID: [...]

[...] operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ therapy does not affect them adversely [see Patient Counseling Information (17)]. Reference ID: [...]

[...] operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ therapy does not affect them adversely [see Patient Counseling Information (17)]. Reference ID: [...]

[...] of this disease, the clinical trial experience with BELVIQ is inadequate to determine if BELVIQ increases the risk for pulmonary hypertension. 6 ADVERSE REACTIONS The following important adverse [...]

[...] of this disease, the clinical trial experience with BELVIQ is inadequate to determine if BELVIQ increases the risk for pulmonary hypertension. 6 ADVERSE REACTIONS The following important adverse [...]

[...] of this disease, the clinical trial experience with BELVIQ is inadequate to determine if BELVIQ increases the risk for pulmonary hypertension. 6 ADVERSE REACTIONS The following important adverse [...]